Tags Archive Navigation
icon
-
Media ReleaseNovartis maintains growth momentum and confirms FY’22 Group guidance
-
Media ReleaseCosentyx® (secukinumab) receives expanded approvals in EU for use in childhood arthritic conditions
-
Media ReleaseSandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
-
Media ReleaseFDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
-
Media ReleaseNovartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions
-
Media ReleaseNovartis erzielt ein solides Umsatz- und Gewinnwachstum. Die starke Performance auf dem Markt befindlicher Marken stützt das Vertrauen in die mittelfristigen Wachstumsaussichten
-
Media ReleaseNovartis: solide croissance du chiffre d’affaires et du bénéfice. La forte performance des marques existantes soutient la confiance dans les prévisions de croissance à moyen terme
-
Media ReleaseNovartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook
-
Media ReleaseSandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio
-
Media ReleaseNovartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility
-
Media ReleaseNovartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
-
Media ReleaseNovartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021
Pagination
- ‹ Previous page
- 1
- …
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- …
- 16
- › Next page